- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent - Delivers Full-Year Net Revenues of $32.753 Billion on a GAAP Basis; Adjusted Net Revenues of $32.733 Billion Increased 15.2 Percent on an Operational Basis - Full-Year Global

NORTH CHICAGO, Ill. , Jan. 3, 2019 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens. AbbVie will host a live webcast of the earnings

NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President, will present at

NORTH CHICAGO, Ill. , Dec. 17, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy.  Effective

NORTH CHICAGO, Ill. , Dec. 13, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may be made from time to time at management's discretion.

NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday, November 27, 2018. Bill Chase , executive vice president, finance and administration, will present at 8

- Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent - Delivers Third-Quarter Net Revenues of $8.236 Billion on a GAAP Basis; Adjusted Net Revenues of $8.236 Billion Increased 18.5 Percent on an Operational Basis - Third-Quarter

NORTH CHICAGO, Ill. , Sept. 17, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2 2018 , before the market opens. AbbVie will host a live webcast of the earnings conference call

NORTH CHICAGO, Ill. , Sept. 7, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018 .

NORTH CHICAGO, Ill. , Aug. 28, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 16 th  Annual Global Healthcare Conference on Wednesday, September 12, 2018. Bill Chase , executive vice president and chief financial